STAT5A and chronic myelogenous leukemia, BCR-ABL1 positive: This would be consistent with recent evidence indicating that combined targeting of STAT3 and STAT5 effectively reversed various forms of tyrosine kinase inhibitor (TKI)-resistance in highly resistant BCR-ABL1T315I chronic myeloid lymphoma (CML) cells [40].